|
[ back to News ]
Press Release Archive
2009 ¦ 2008 ¦ 2007 ¦ 2006
December 9, 2009
Concert
Pharmaceuticals Broadens Management Team and Expands Product Advisory Board
November 9, 2009
Concert
Pharmaceuticals Initiates Phase 1b Clinical Trial of CTP-518, Protease Inhibitor
for Treatment of HIV; Concert Earns $12 Million Milestone from
GlaxoSmithKline
November 3, 2009
Concert Pharmaceuticals to Participate
on a Private Company Panel at the Merriman Curhan Ford 6th Annual Investor
Summit
October 29, 2009
Concert
Pharmaceuticals’ Roger Tung Awarded 2009 Mass High Tech All Star Award
October 20, 2009
Concert
Pharmaceuticals to Present at Second Annual Boston Biotech R&D
Conference
October 13, 2009
Concert Pharmaceuticals Selected by AlwaysOn as
an OnDC Top 100 Winner; Recognized for Innovative Technology for Game-Changing
New Medicines
September 14, 2009
Concert Pharmaceuticals Presents Clinical Results
Demonstrating Reduced Drug-Drug Interactions with a Deuterium-Modified Compound;
Phase I Results Presented at American College of Clinical Pharmacology
September 3, 2009
Concert
Pharmaceuticals to Present at the Thomas Weisel Partners 2009 Healthcare
Conference on September 10, 2009
August 18, 2009
Concert
Pharmaceuticals' Justine Koenigsberg Named President of NIRI Boston for
2009-2010
June 2, 2009
Concert
Pharmaceuticals and GlaxoSmithKline Form Alliance to Develop Novel Deuterium
Modified Drugs
June 1, 2009
Concert Pharmaceuticals to Participate in the
Private Company Forum at the 30th Annual Goldman Sachs Global Healthcare
Conference
May 11, 2009
Concert
Pharmaceuticals Granted Patents on Deuterium-Modified Compounds
March 16, 2009
Concert
Pharmaceuticals Announces Positive Results from Phase I Clinical Study of
CTP-347; First Clinical Demonstration of Concert's Technology Platform
March 9, 2009
Concert
Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care
Conference on March 16, 2009
January 5, 2009
Concert Pharmaceuticals to
Present at the 27th Annual J.P. Morgan Healthcare Conference on Monday, January
12
[ back to top ]
November 24, 2008
Concert Pharmaceuticals to Present at the
Piper Jaffray Health Care Conference
October 28, 2008
Concert Pharmaceuticals to Present at the
Oppenheimer 19th Annual Healthcare Conference
October 27, 2008
Concert Pharmaceuticals
Announces Preclinical Results Suggesting Potential for Once Daily Dosing of
Novel Oxazolidinone Antibiotic; Findings Presented at ICAAC/IDSA
October 15, 2008
Concert Pharmaceuticals to Present at
First Annual Boston Biotech R&D Conference
October 6, 2008
Steven Bernitz Joins Concert
Pharmaceuticals as Chief Business Officer
September 29, 2008
Concert Pharmaceuticals to Present
at the JMP Securities Healthcare Focus Conference
September 25, 2008
Concert Pharmaceuticals
Presents Preclinical Results Supporting Co-Administration of CTP-347 and
Tamoxifen; Results Presented at the North American Menopause Society's 2008
Annual Meeting
September 25, 2008
Concert Pharmaceuticals Initiates CTP-347
Phase I Clinical Trial; Potential Best-in-Class Non-Hormonal Treatment for
Vasomotor Symptoms
June 24, 2008
Concert Pharmaceuticals Named
One of the “Fierce 15" Biotech Companies of 2008
April 30 , 2008
Concert Pharmaceuticals
Raises $37 Million in Series C Financing
April 16 , 2008
Concert
Pharmaceuticals Announces Appointment of Justine Koenigsberg as Senior Director,
Corporate Communications and Investor Relations
March 11, 2008
Concert
Pharmaceuticals to Present at the Cowen and Company 28th Annual Healthcare
Conference
February 25, 2008
Concert Pharmaceuticals Profiled in
BioCentury
January 3, 2008
Concert
Pharmaceuticals Names W. James O’Shea and Daniel Grau to Product Advisory
Board
January 2, 2008
Concert
Pharmaceuticals to Present at the 26th Annual JPMorgan Healthcare
Conference
[ back to top ]
December 18, 2007
Concert
Pharmaceuticals Appoints Dr. Ronald W. Barrett to the Company’s Board of
Directors
December 13, 2007
Concert
Pharmaceuticals Strengthens Executive Leadership Team
[ back to top ]
December 11, 2006
Peter Barton
Hutt Appointed to Concert Pharmaceuticals
November 30, 2006
Concert
Pharmaceuticals Raises $48.5 Million in Series B Financing
September 15, 2006
Concert
President and CEO Roger Tung Interviewed by SBS News
July 17, 2006
Concert
Pharmaceuticals, Inc. Announces Financing of its Series A Round
[ back to top ]
[ back to top ]
|
